625 results on '"Greenberg, William A."'
Search Results
102. Correlation functionals of infinite volume quantum spin systems
103. Thermodynamic states of classical systems
104. A Capital Markets View of Mortgage Servicing Rights
105. Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder
106. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans
107. Clinical Supervision of the Treatment of a Patient with Deeply Held Convictions
108. Applications of the Initial Value Problem
109. Albedo Operators, H-Equations and Representation of Solutions
110. Conservative Kinetic Models
111. Non-Dissipative and Non-Symmetric Kinetic Models
112. Semigroup Factorization and Reconstruction
113. Elements of Linear Kinetic Theory
114. Applications of the Stationary Theory
115. Equivalence of Differential and Integral Formulations
116. Boundary Value Problems in Abstract Kinetic Theory
117. Indefinite Sturm-Liouville Problems
118. Strictly Dissipative Kinetic Models
119. Time Dependent Kinetic Equations: Method of Characteristics
120. Kinetic Equations on Finite Domains
121. Time Dependent Kinetic Equations: Semigroup Approach
122. An enzyme library approach to biocatalysis: Development of nitrilases for enantioselective production of carboxylic acid derivatives
123. Iminosugar-Based Glycosyltransferase Inhibitors
124. Aldolase Enzymes for Complex Synthesis
125. Expanding the Scope of Aldolases as Tools for Organic Synthesis
126. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder
127. Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials
128. Focused Opportunities for Resident Education on Today’s Inpatient Psychiatric Units
129. A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder
130. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
131. Efficacy and Safety of Levomilnacipran Sustained Release 40 mg, 80 mg, or 120 mg in Major Depressive Disorder
132. Extensionality, Proper Classes, and Quantum Non-Individuality.
133. Cycloaddition of 2-thiazolines and acyl ketenes under acidic conditions results in bicyclic 1,3-oxazinones and not 6-acylpenams as earlier reported
134. Some things just don't belong
135. Preparing for Nuclear War: The Psychological Effects
136. ChemInform Abstract: Expanding the Scope of Aldolases as Tools for Organic Synthesis
137. Chemoenzymatic elaboration of monosaccharides using engineered cytochrome P450 BM3 demethylases
138. THE MULTIPLE PERSONALITY
139. General Crook and Counterinsurgency Warfare
140. ChemInform Abstract: Recent Advances in Aldolase‐Catalyzed Synthesis of Unnatural Sugars and Iminocyclitols
141. In Honor of Professor Chi‐Huey Wong on the Occasion of His 60th Birthday
142. Cysteine‐Free Peptide and Glycopeptide Ligation by Direct Aminolysis
143. ChemInform Abstract: D-Fructose-6-phosphate Aldolase-Catalyzed One-Pot Synthesis of Iminocyclitols.
144. ChemInform Abstract: Probing Glycans with the Copper(I)-Catalyzed [3 + 2] Azide-Alkyne Cycloaddition
145. Recent Advances in Aldolase-Catalyzed Synthesis of Unnatural Sugars and Iminocyclitols
146. Probing Glycans With the Copper(I)-Catalyzed [3+2] Azide-Alkyne Cycloaddition
147. Recent Advances in Aldolase-Catalyzed Asymmetric Synthesis
148. Recent Advances in Aldolase-Catalyzed Asymmetric Synthesis
149. Ziprasidone for Schizophrenia and Bipolar Disorder: A Review of the Clinical Trials
150. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.